REGN (Regeneron Pharmaceuticals) Earnings per share growth rate in current year

REGN (regeneron.com) - company brandmark

Regeneron Pharmaceuticals (REGN) ensures operational stability through its own high-tech manufacturing plants in the US and Ireland. The annual growth rate of net income per share demonstrates the market consensus, where 54.20 reflects the latest value of the metric. Dominance in the sector is sustained by patents on blockbuster drugs, while success is based on unique genetic developments that defeat severe diseases.

REGN (Regeneron Pharmaceuticals) Earnings per share growth in current year history from 07/04/2022 to 11/18/2026

Comprehensive metric breakdowns and analytics for Regeneron (REGN)

Basic company analysis:Regeneron Inc. REGN
Brand item of regeneron.com

This indicator measures the annual growth rate of earnings per share, allowing for an assessment of business scaling efficiency and the pace of capital generation. By analyzing EPS dynamics compared to the previous year, an investor can identify risks of revenue stagnation for Regeneron Pharmaceuticals (REGN) due to biosimilar expansion or clinical trial failures, which is critical for the long-term valuation of the asset.